RNA Structure Viewer

SMN2 exon 7 + intron 7 region. Contains the ISS-N1 silencer targeted by Nusinersen (Spinraza), the first FDA-approved ASO drug for spinal muscular atrophy.

DMD exon 51 — target of Eteplirsen (Exondys 51), the first exon-skipping ASO for Duchenne muscular dystrophy.

MAPT (tau) exon 10 + intron 10 stem-loop. Mutations here cause frontotemporal dementia by disrupting tau isoform balance.

Pre-miR-21, a key oncogenic microRNA overexpressed in most cancers. Anti-miR ASOs targeting miR-21 are in therapeutic development.